Ramis J, Conte L, Segado X, Forn J, Lauroba J, Calpena A, Escribano E, Domenech J
Department of Pharmacokinetics, J. Uriach & Cía. S.A., Barcelona Spain.
Arzneimittelforschung. 1997 Oct;47(10):1139-44.
Flutrimazole (1-[(2-fluorophenyl)(4-fluorophenyl)phenylmethyl]-1 H-imidazole, CAS 119006-77-8, UR-4056) is a new wide spectrum local imidazolic antifungal agent that has already been formulated as a dermal cream (FDC). A comparative study was carried out of the release of flutrimazole from two emulsions in which the drug has been incorporated differently: one dissolved in the oily phase (E24) and the other dispersed in the aqueous formulation phase (E25). Based on the E25 formulation, two more dermal creams were prepared, E27 with benzyl alcohol and E28 with diazolidinyl urea as preservative agents. A comparative study of transdermal penetration including E27, E28, FDC (reference 1% flutrimazole dermal cream) and 1% flutrimazole hydroalcoholic solution was also performed. An amount of the sample dosage form containing 10 mg of flutrimazole was applied to a Franz type cell. The penetration membrane used was cellulose acetate in the release studies and human skin provided by a plastic surgery clinic in the transdermal penetration study. The amount released after 7 h was 36.3 +/- 4.9 micrograms when flutrimazole was dissolved (E24) and 35.9 +/- 5.3 micrograms when flutrimazole was dispersed (E25). Although the differences were not significant, the cream with dispersed flutrimazole was selected for further penetration studies due to its better stability observed in previous studies. The amounts of drug penetrated after 44 h were 31.3, 41.5, 38.3 and 186.5 micrograms for E27, E28, FDC dermal creams and topical hydroalcoholic solution, respectively. The solution showed a statistically significant difference (p < 0.05) from the other formulations, however, no differences were observed between the dermal cream formulations. No differences were neither obtained between the different dermal creams when the amount of drug retained in the skin was compared. This allows to assert that the excipients used do not have different influences on transdermal penetration. In all cases, the mean quantity penetrated in relation to the dose applied was at most 0.5%. These results allow to infer that flutrimazole shows scarce transdermal penetration. Further, the amount of flutrimazole retained per gram of skin is more than 100 times the MIC per gram obtained in previous in vitro studies. It may be assumed that the topical application of the new formulations assayed would allow to obtain a good therapeutic response.
氟曲马唑(1-[(2-氟苯基)(4-氟苯基)苯基甲基]-1H-咪唑,CAS 119006-77-8,UR-4056)是一种新型广谱局部咪唑类抗真菌剂,已被制成皮肤乳膏(FDC)。对氟曲马唑在两种乳液中的释放情况进行了比较研究,药物在这两种乳液中的加入方式不同:一种溶解在油相中(E24),另一种分散在水性制剂相中(E25)。基于E25配方,又制备了两种皮肤乳膏,E27使用苯甲醇作为防腐剂,E28使用双咪唑烷基脲作为防腐剂。还进行了包括E27、E28、FDC(对照1%氟曲马唑皮肤乳膏)和1%氟曲马唑水醇溶液的透皮渗透比较研究。将含有10mg氟曲马唑的样品剂型应用于Franz型扩散池。在释放研究中使用的渗透膜是醋酸纤维素,在透皮渗透研究中使用的是由一家整形手术诊所提供的人体皮肤。当氟曲马唑溶解时(E24),7小时后释放的量为36.3±4.9微克,当氟曲马唑分散时(E25),释放量为35.9±5.3微克。虽然差异不显著,但由于在先前研究中观察到其稳定性更好,所以选择氟曲马唑分散的乳膏进行进一步的渗透研究。44小时后,E27、E28、FDC皮肤乳膏和局部水醇溶液的药物渗透量分别为31.3、41.5、38.3和186.5微克。该溶液与其他制剂相比有统计学显著差异(p<0.05),然而,皮肤乳膏制剂之间未观察到差异。比较皮肤中保留的药物量时,不同皮肤乳膏之间也未获得差异。这表明所用辅料对透皮渗透没有不同影响。在所有情况下,相对于给药剂量的平均渗透量最多为0.5%。这些结果表明氟曲马唑的透皮渗透较少。此外,每克皮肤中保留的氟曲马唑量比先前体外研究中每克获得的最低抑菌浓度(MIC)多100倍以上。可以假定所检测的新制剂局部应用将能获得良好的治疗反应。